###begin article-title 0
###xml 34 46 34 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in Acute Myeloid Leukemia
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 22 45 22 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mixed Lineage Leukemia </italic>
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 672 675 672 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 762 767 762 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA </italic>
###xml 807 811 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
Translocations of the Mixed Lineage Leukemia (MLL) gene occur in a subset (5%) of acute myeloid leukemias (AML), and in mixed phenotype acute leukemias in infancy - a disease with extremely poor prognosis. Animal model systems show that MLL gain of function mutations may contribute to leukemogenesis. Wild-type (wt) MLL possesses histone methyltransferase activity and functions at the level of chromatin organization by affecting the expression of specific target genes. While numerous MLL fusion proteins exert a diverse array of functions, they ultimately serve to induce transcription of specific genes. Hence, acute lymphoblastic leukemias (ALL) with MLL mutations (MLLmu) exhibit characteristic gene expression profiles including high-level expression of HOXA cluster genes. Here, we aimed to relate MLL mutational status and tumor suppressor gene (TSG) methylation/expression in acute leukemia cell lines.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 154 157 154 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 282 285 282 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 341 353 341 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 420 423 420 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 604 616 604 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 620 625 620 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 677 680 677 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 868 871 868 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 932 937 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 952 960 952 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL </italic>
###xml 1015 1019 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 971 976 <span type="species:ncbi:10090">mouse</span>
Using MS-MLPA (methylation-specific multiplex ligation-dependent probe amplification assay), methylation of 24 different TSG was analyzed in 28 MLLmu and MLLwt acute leukemia cell lines. On average, 1.8/24 TSG were methylated in MLLmu AML cells, while 6.2/24 TSG were methylated in MLLwt AML cells. Hypomethylation and expression of the TSG BEX2, IGSF4 and TIMP3 turned out to be characteristic of MLLmu AML cell lines. MLLwt AML cell lines displayed hypermethylated TSG promoters resulting in transcriptional silencing. Demethylating agents and inhibitors of histone deacetylases restored expression of BEX2, IGSF4 and TIMP3, confirming epigenetic silencing of these genes in MLLwt cells. The positive correlation between MLL translocation, TSG hypomethylation and expression suggested that MLL fusion proteins were responsible for dysregulation of TSG expression in MLLmu cells. This concept was supported by our observation that Bex2 mRNA levels in MLL-ENL transgenic mouse cell lines required expression of the MLL fusion gene.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 65 77 65 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
These results suggest that the conspicuous expression of the TSG BEX2, IGSF4 and TIMP3 in MLLmu AML cell lines is the consequence of altered epigenetic properties of MLL fusion proteins.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 22 45 22 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mixed Lineage Leukemia </italic>
###xml 46 49 46 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 320 323 320 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOXA </italic>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 498 501 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 608 612 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 654 681 654 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">brain expressed X-linked 2 </italic>
###xml 682 686 682 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 704 708 704 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX1</italic>
###xml 711 712 711 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 734 739 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 838 839 838 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 840 841 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 877 882 877 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 913 916 913 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 924 928 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 939 942 939 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 988 991 988 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 1054 1059 1054 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 1103 1106 1103 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 1114 1115 1114 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 726 732 <span type="species:ncbi:9606">people</span>
Translocations of the Mixed Lineage Leukemia (MLL) gene occur in a subset of acute leukemias. The correlation between MLL translocations and expression of specific gene clusters is so evident that "mixed lineage leukemia", originally applied to biphenotypic acute leukemia cells, is now used to describe the MLL mutant (MLLmu) acute leukemias [1]. High expression levels of a set of HOXA cluster genes are characteristic of MLL mutations in primary acute lymphoblastic leukemia (ALL) cells, and in MLLmu ALL cell lines [1,2]. For acute myeloid leukemia (AML) cell lines, a similar correlation exists between MLL translocations and expression of the gene brain expressed X-linked 2 (BEX2, formerly called BEX1) [3]. In healthy people, BEX2 is expressed in the brain and, more weakly, in pancreas and testis, but not in hematopoetic cells [3,4]. In leukemia cell lines, we found BEX2 expression to be restricted to MLLmu AML. MLL wild-type (MLLwt) AML and ALL cell lines and, notably, also MLLmu ALL cell lines do not transcribe this gene, suggesting that BEX2 expression might be a diagnostic marker for MLLmu AML [3].
###end p 9
###begin p 10
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 618 623 618 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 626 629 626 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 644 647 644 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 657 658 657 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Several lines of evidence indicate that epigenetic mechanisms are responsible for the regulation of BEX2 expression: (i) the BEX2 promoter is methylated in MLLwt and unmethylated in MLLmu AML cell lines, thus demonstrating an inverse correlation between gene expression and promoter methylation [5]; (ii) demethylating agents and inhibitors of histone deacetylases (HDAC) induce BEX2 expression in MLLwt cells [5]; (iii) chromatin immunoprecipitation experiments show that histone acetylation plays a role in BEX2 regulation: immunoprecipitation of acetylated histone H3 coprecipitates chromatin from the 5' region of BEX2 in MLLmu, but not in MLLwt cells [5].
###end p 10
###begin p 11
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX1 </italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
BEX1 and BEX2 have recently been described as epigenetically controlled candidate tumor suppressor genes (TSG) in malignant glioma [6]. Promoter hypermethylation of TSG is often seen in malignant diseases and, according to a widely held view, contributes to the rise of malignant cell clones by restraining tumor suppressor gene expression [7]. Moreover, unique profiles of hypermethylated CpG islands have been described which are characteristic of different neoplasias [8,9].
###end p 11
###begin p 12
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 234 237 234 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 322 325 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 368 404 368 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunoglobulin superfamily member 4 </italic>
###xml 405 454 405 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4/CADM1), Retinoic acid receptor beta (RARB) </italic>
###xml 458 505 458 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tissue inhibitor of matrix metalloproteinase 3 </italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 523 526 523 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 569 573 569 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
We applied a multiplex methylation detection assay to find out whether the connection between the MLL mutational status and promoter methylation is unique to BEX2 or if this correlation applies to other TSG as well. Results show that MLLwt AML cell lines exhibit a higher propensity for TSG promoter hypermethylation than MLLmu cell lines. This is especially true for Immunoglobulin superfamily member 4 (IGSF4/CADM1), Retinoic acid receptor beta (RARB) and Tissue inhibitor of matrix metalloproteinase 3 (TIMP3), all with MLL-dependent methylation profiles resembling BEX2. According to methylation-specific PCR (MSP), primary AML cells without rearrangement of the MLL gene also show a preference for TSG hypermethylation.
###end p 12
###begin p 13
Our experimental results suggest that MLLmu proteins enhance the expression of distinct TSG and that this might be the consequence of altered epigenetic regulatory mechanisms of the fusion proteins.
###end p 13
###begin title 14
Results and Discussion
###end title 14
###begin title 15
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Methylation patterns of TSG differ in MLLmu and MLLwt cell lines
###end title 15
###begin p 16
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 504 507 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 537 540 537 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 641 642 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 643 644 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 771 775 771 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 790 794 790 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
Hypermethylation of CpG islands in the promoter regions of TSG occurs widely in malignancy, resulting in transcriptional inactivation which promotes cancerogenesis [7]. Unique profiles of hypermethylated CpG islands have been described, being characteristic of different neoplasias [8,9]. BEX2 is a newly described TSG, which is silenced by hypermethylation in malignant glioma [6]. With leukemia/lymphoma cell lines as model systems, we have shown that BEX2 hypomethylation and gene expression typifies MLLmu AML [3]. BEX2 silencing in MLLwt cells is the result of epigenetic mechanisms like promoter methylation and histone deacetylation [3,5]. Here, we set out to elucidate whether the described correlation between promoter hypomethylation and genetically rearranged MLL is peculiar to BEX2, or whether other TSG display similar features.
###end p 16
###begin p 17
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 480 483 480 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 502 505 502 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 582 585 582 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 671 674 671 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was performed to assess the methylation status of 24 TSG in 28 acute leukemia cell lines, 50% with MLL translocations (see Additional file 1). ALL-derived cell lines showed a higher percentage of methylated TSG than AML cell lines (Fig. 1). The mean number of methylated TSG in ALL cell lines was independent of MLL mutational status (Fig. 1). In contrast, 25% of all TSG analyzed were methylated in MLLwt, but only 7% in MLLmu AML cell lines (Fig. 1). Provided that the TSG tested are representative, MLLmu AML cell lines display a significantly lower tendency to TSG hypermethylation than MLLwt cell lines.
###end p 17
###begin p 18
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Low tendency for TSG methylation in <italic>MLL </italic>mu AML cell lines</bold>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 268 271 268 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 287 290 287 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Low tendency for TSG methylation in MLL mu AML cell lines. Methylation status of 24 TSG was determined by MS-MLPA (see also: Additional file 1). Mean numbers of methylated TSG and standard deviations in the different groups of leukemia cell lines are shown. Note that MLLmu AML, but not MLLmu ALL cell lines show reduced TSG methylation.
###end p 18
###begin title 19
###xml 22 40 22 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4, RARB </italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Methylation status of BEX2, IGSF4, RARB and TIMP3 is indicative of MLLmu AML
###end title 19
###begin p 20
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 349 352 349 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 545 550 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
Expression array analysis allows classification of tumors, including the discrimination of acute leukemias with/without MLL translocations [1]. Likewise, profiles of promoter hypermethylation are unique for different types of cancer and have also been used to identify lymphomatous entities [8-12]. We evaluated our MS-MLPA data to find out whether MLLmu and MLLwt cell lines could be distinguished via their respective TSG methylation patterns (see Additional file 1). In addition to the 24 TSG included in this assay, we tested methylation of BEX2 by a methylation-sensitive DNA restriction- and quantitative real-time PCR-assay.
###end p 20
###begin p 21
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 70 73 70 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 80 83 80 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 316 319 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 326 329 326 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 424 427 424 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Promoter methylation of TSG BEX2, IGSF4, RARB and TIMP3 distinguished MLLmu and MLLwt AML: 0/7 MLLmu and 6/7 MLLwt AML cell lines exhibited methylation of at least two of these four TSG (p-value = 0.002, Fisher's exact test) (Fig. 2). Neither these four genes nor any other set of TSG analyzed distinguished between MLLmu and MLLwt ALL cell lines, suggesting that a myeloid gene expression background was obligatory for the MLL-specific methylation pattern (see Fig. 2, Additional file 1).
###end p 21
###begin p 22
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TSG methylation predictive for classification of acute leukemia cell lines</bold>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 334 352 332 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4, RARB </italic>
###xml 356 362 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 391 394 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 413 416 411 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 495 499 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 501 506 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 510 516 508 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 548 554 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 601 613 599 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK1, FHIT </italic>
###xml 617 622 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73 </italic>
###xml 725 731 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 735 739 731 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
TSG methylation predictive for classification of acute leukemia cell lines. Methylation was assessed by MS-MLPA (see also Additional file 1) or by DNA digestion with methylation-sensitive HhaI plus promoter-specific quantitative real-time PCR (for analysis of BEX2). Green: methylation level >/= 10%; yellow: methylation level < 10%. BEX2, IGSF4, RARB and TIMP3 are methylated in ALL and in MLLwt AML, but not in MLLmu AML. This correlation is statistically significant with p-values < 0.05 for BEX2, RARB and TIMP3 and with a p-value of 0.051 for IGSF4 (Fisher's exact test). Methylation analysis of DAPK1, FHIT and TP73 discriminates between ALL and AML cell lines (p-values </= 0.01, Fisher's exact test). Other TSG (e.g. BRCA2 and ESR1) are methylated or unmethylated in the majority of cell lines with no preference for subtype.
###end p 22
###begin p 23
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 272 279 272 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 410 415 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DAPK1</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FHIT</italic>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP73</italic>
###xml 521 522 521 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 699 717 699 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4, RARB </italic>
###xml 721 727 721 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 758 761 758 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Most of the 24 TSG analyzed did not allow the histological origin of the cells to be inferred, being either methylated (e.g. ESR1) or unmethylated (e.g. BRCA2) in the majority of cell lines (see Fig. 2, Additional file 1). Furthermore, deletions, notably those of the TSG CDKN2A and CDKN2B, occurred in ALL as well as in AML cell lines (see Additional file 1). However, the methylation pattern of three genes (DAPK1, FHIT, TP73) was highly characteristic (p-values = 0.01, Fisher's exact test) of either ALL or AML (Fig. 2). These results show that analysis of TSG methylation may also be used to recognize distinct leukemic entities. Noteworthy in the context of our study, methylation patterns of BEX2, IGSF4, RARB and TIMP3 allowed discrimination between MLLmu and wt AML cell lines (Fig. 2).
###end p 23
###begin p 24
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HhaI</italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 303 325 303 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 and TIMP3 </italic>
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 462 465 462 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
MS-MLPA is a screening technique and obtained results rely on the analysis of one single CpG-site in the promoter region. To verify the validity of the methylation status as determined by MS-MLPA or HhaI-restriction-sensitive PCR assay (for BEX2), we performed MSP after bisulfite conversion of DNA for BEX2, IGSF4 and TIMP3 (see Additional file 2). The respective CpGs tested by MSP and MS-MLPA were located at different promoter sites. The accuracy of MS-MLPA/HhaI-restriction-sensitive PCR to predict the methylation status of these three TSG as determined by MSP was reassuringly high (83%), supporting the validity of MS-MLPA for use in our screening.
###end p 24
###begin p 25
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 62 74 62 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
In conclusion, most MLLwt cell lines show hypermethylation of BEX2, IGSF4 and TIMP3, while MLLmu cell lines are preferentially unmethylated.
###end p 25
###begin title 26
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Methylation of tumor suppressor genes in primary MLLmu and MLLwt AML cells
###end title 26
###begin p 27
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 390 393 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 400 403 400 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
CpG island hypermethylation occurs more often in cell lines than in primary tumor cells [11,13]. Controversial opinions exist on the question whether or not cell lines, including leukemia cell lines, show the same methylation profiles as the analogous primary cells [13-15]. To investigate the possible concordance of TSG methylation in cell lines and primary cells, we tested samples from MLLmu and MLLwt AML patients for TSG methylation. MS-MLPA assay detected low numbers of methylated TSG (mean 0.5/24 +/- 1.0 TSG) in primary AML cells, which is in accordance with earlier findings applying the same technique [16]. MSP has been shown to be a suitable and more sensitive technique for primary AML samples than MS-MLPA [17].
###end p 27
###begin p 28
###xml 153 171 153 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4, RARB </italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 338 341 338 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 431 435 431 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB</italic>
###xml 517 523 517 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 562 565 562 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 603 606 603 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4</italic>
###xml 722 725 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 789 790 789 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
###xml 728 735 <span type="species:ncbi:9606">patient</span>
Therefore, we performed MSP after bisulfite conversion of DNA and detected methylated and unmethylated TSG promoter sequences using primers specific for BEX2, IGSF4, RARB and TIMP3, the most informative genes in our system (Fig. 3). For BEX2, IGSF4 and TIMP3, MSP indicated a trend towards an association between promoter methylation and MLLwt status (see Fig. 3B and Additional file 3). This correlation could not be observed for RARB, rendering this gene less interesting for our study. Bisulfite sequencing of the IGSF4 promoter region confirmed MSP results: MLLwt AML patients (#9, #14 and #15) and MLLwt cell line U-937 harbored clones with CpG methylation adjacent to the transcriptional start site of IGSF4, unlike MLLmu patient #23 and cell line THP-1 (see Fig. 4, Additional file 3).
###end p 28
###begin p 29
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TSG methylation in primary AML samples</bold>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4</italic>
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 135 138 135 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 387 390 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 456 468 456 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 472 478 472 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 558 569 558 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4</italic>
###xml 571 576 571 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 598 601 598 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 621 624 621 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">Patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 604 612 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
TSG methylation in primary AML samples. Methylation status was assessed by MSP for BEX2, IGSF4, TIMP3 and RARB in a panel of MLLwt and MLLmu AML patients. A) Representative results for BEX2 MSP are shown. Patients #1 - #17 carry MLLwt, patients #18 - #40 harbor MLL rearrangements (see Additional file 3). B) Summary of methylation data obtained by MSP in patients. Lower percentages of MLLmu patients than MLLwt patients show promoter hypermethylation of BEX2, IGSF4 and TIMP3 (see also Additional file 3). C) Note that methylation of two out of three TSG (BEX2, IGSF4, TIMP3) is more frequent in MLLwt patients than in MLLmu patients.
###end p 29
###begin p 30
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Bisulfite sequencing of the <italic>IGSF4 </italic>promoter region</bold>
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 458 461 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 492 495 492 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 464 471 <span type="species:ncbi:9606">patient</span>
Bisulfite sequencing of the IGSF4 promoter region. The IGSF4 promoter region (559 bp, 52 CpG sites) was sequenced after bisulfite conversion of DNA in two cell lines and selected AML patients. CpGs are represented as open dots (unmethylated) or filled dots (methylated). In MLLwt AML patients and in the MLLwt cell line U-937 clones with CpG methylation next to the transcriptional start site (TSS) were detected whereas no methylation was detectable in the MLLmu patient analyzed and in the MLLmu cell line THP-1. Note that CpG sites analyzed by the MS-MLPA probe (green) and MSP primers (red) are not identical.
###end p 30
###begin p 31
###xml 67 79 67 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 287 299 287 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 329 332 329 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 343 346 343 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
Using methylation of at least two out of the three relevant genes (BEX2, IGSF4 and TIMP3) as classifier for the MLL mutational status, the true positive identification rate (sensitivity) for MLLmu samples was 73%, with a specificity of 58%, supporting the conclusion that methylation of BEX2, IGSF4 and TIMP3 is more frequent in MLLwt than in MLLmu patients (Fig. 3C). Testing a larger cohort of patients will be necessary to confirm a statistically significant positive correlation between MLL mutational status and TSG methylation.
###end p 31
###begin title 32
Inverse correlation of TSG methylation and expression
###end title 32
###begin p 33
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 597 602 597 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 722 726 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARA</italic>
###xml 755 761 755 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARA2 </italic>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 961 964 961 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 1004 1019 1004 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">of BEX2, IGSF4 </italic>
###xml 1023 1029 1023 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 1034 1037 1034 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Hypermethylation of CpG islands in the promoter regions of TSG generally leads to the silencing of the respective genes [18,19]. To test whether BEX2, IGSF4, RARB and TIMP3 were epigenetically regulated, we analyzed mRNA expression of these genes in cell lines by quantitative real-time PCR. Figure 5 shows that three of the four genes analyzed (BEX2, IGSF4 and TIMP3) demonstrated an inverse correlation between TSG promoter methylation and gene expression consistent with epigenetic gene regulation. Predictive value for true methylation of these genes was 0.93, and accuracy 0.94. In contrast, RARB remained silent in most cell lines, independent of methylation status (Fig. 5). A similar result has been described for RARA: primary AML cells show low RARA2 expression although the promoter is not methylated confirming that regulation of gene transcription is a multi-factor process, not solely reliant on promoter methylation/demethylation [20]. Thus, (i) MLLmu AML cell lines express higher levels of BEX2, IGSF4 and TIMP3 than MLLwt cell lines, and (ii) these three TSG appear to be regulated by epigenetic mechanisms.
###end p 33
###begin p 34
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inverse correlation between TSG methylation and expression</bold>
###xml 119 131 119 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB</italic>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 652 664 652 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB</italic>
Inverse correlation between TSG methylation and expression. Hypomethylation (yellow) parallels RNA expression (red) of BEX2, IGSF4 and TIMP3 in MLLmu AML. MLLwt AML cell lines show hypermethylation (light green) and transcriptional silencing (green) of these. In contrast, RARB expression is low (green) even in cell lines that carry the unmethylated promoter (yellow). Excluding RARB, TSG hypermethylation inversely correlated with gene transcription in 94% of the cases. TSG methylation status is shown as determined by MS-MLPA (see Additional file 1). Gene expression was assessed in triplicates by quantitative real-time PCR (RT-PCR) analysis. For BEX2, IGSF4 and TIMP3, cell line IMS-M1 was applied as calibrator; for RARB, expression levels in cell line 697 were set as 1. Cell lines that reached relative expression levels >/= 0.05 were considered positive (red).
###end p 34
###begin p 35
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 200 203 200 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
RARB was excluded from further studies, as we neither observed an inverse correlation between RARB promoter methylation and gene expression in cell lines nor did we see a positive correlation between MLLmu and RARB hypomethylation in primary AML cells.
###end p 35
###begin p 36
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 252 255 252 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 313 325 313 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 428 431 428 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 570 573 570 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
According to our findings, TSG hypomethylation and mRNA expression are characteristic features of MLLmu AML cells. This is in apparent conflict with the notion that MLL fusion proteins act as strong oncogenes, a view that is supported by the fact that MLLmu confers a dismal prognosis in AML. We hypothesize that BEX2, IGSF4 and TIMP3 are sentinel MLL fusion gene targets, their function being overridden by the strong oncogene MLLmu. A better understanding of how MLL fusion proteins impede TSG promoter methylation might help to illuminate a novel epigenetic role for MLLmu in leukemic cells.
###end p 36
###begin title 37
DNA demethylation and histone acetylation induce expression of TSG
###end title 37
###begin p 38
###xml 35 47 35 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 250 253 250 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 601 604 601 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 658 661 658 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
To verify epigenetic regulation of BEX2, IGSF4 and TIMP3, we applied the DNA-demethylating agent 5-Aza-2'-deoxycytidine (Aza) and the HDAC inhibitor trichostatin A (TSA). Our previous results had shown that these agents induced expression of BEX2 in MLLwt AML cell lines [5]. We show here that Aza and TSA also triggered mRNA expression of IGSF4 and TIMP3 (Table 1). To confirm activity of TSA, histone H4K12 acetylation, a modification associated with active transcription, was analyzed (see Additional file 4). These results confirmed that epigenetic mechanisms are responsible for TSG silencing in MLLwt cell lines and suggest that TSG hypomethylation in MLLmu cell lines might be caused by alterations of epigenetic MLL functions as result of the various translocations.
###end p 38
###begin p 39
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Effects of Aza and TSA on TSG expression in MLLwt AML cell lines.
###end p 39
###begin p 40
###xml 318 324 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 328 334 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
Induction of TSG expression by Aza (5 muM, 4 d) and TSA (2 muM, 1 d) when compared to untreated control cells: - < 2-fold, + >/= 2-fold; ++ >/= 10-fold, +++ >/= 100-fold gene expression. Expression levels were determined by quantitative real-time PCR. Note that cell line SKM-1 shows hypomethylation and expression of IGSF4 and TIMP3 (Fig. 5). Experiments were performed at least twice. Brackets: effect variable.
###end p 40
###begin title 41
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL</italic>
Bex2 transcription depends on expression of MLL-ENL
###end title 41
###begin p 42
###xml 149 157 149 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL </italic>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
###xml 453 458 <span type="species:ncbi:10090">mouse</span>
To verify whether MLL fusion proteins were responsible for altered expression of TSG, we applied a mouse bone marrow cell line system that expresses MLL-ENL fused to the ligand-binding domain of the estrogen receptor. Removal of 4-hydroxytamoxifen (4-OHT) from the medium tethers MLL-ENL to a heat shock protein complex, thereby blocking the activation of the fusion protein [21]. Withdrawal of 4-OHT led to a marked decrease of Bex2 expression in this mouse cell system confirming that MLL fusion proteins serve to upregulate this gene (Fig. 6).
###end p 42
###begin p 43
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MLL fusion proteins regulate <italic>Bex2 </italic>expression</bold>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL</italic>
###xml 116 124 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL </italic>
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2</italic>
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL </italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 331 338 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL</italic>
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
MLL fusion proteins regulate Bex2 expression. In presence of 4-OHT (100 nM) MLL-ENL-ERtm mouse cell lines expressed MLL-ENL and Bex2. Withdrawal of 4-OHT for seven to nine days induced downregulation of MLL-ENL and suppression of Bex2 transcription. Bex2 expression levels with standard deviations were determined in two different MLL-ENL-ERtm cell line clones by quantitative real-time PCR analysis.
###end p 43
###begin p 44
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
These results suggest that expression of TSG in MLLmu cell lines is attributable to the presence of MLL fusion proteins, raising the question whether the MLL fusion proteins directly target TSG promoters by blocking DNA methylation processes, or whether these effects are secondary.
###end p 44
###begin p 45
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 283 291 283 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 498 501 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
It is difficult to attribute a specific oncogenic function to any single region of MLL fusion genes. Characteristic of the complexity of the situation is that many MLL translocations are reciprocal, and that both fusion genes are transcribed and may function oncogenically. However, MLL-ENL alone was sufficient to induce Bex2 in the transgene system indicating that the reciprocal fusion product was not required for regulation of this TSG. Furthermore, we observed TSG hypomethylation in various MLLmu cell lines with a variety of fusion partners. Together, these observations suggested that the inhibitory effect of MLL fusion genes on TSG promoter methylation was mediated by the N-terminal part of MLL and not by the fusion partner.
###end p 45
###begin p 46
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 455 459 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1073 1078 1073 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Kip1 </sup>
###xml 1085 1091 1085 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Ink4c </sup>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1095 1097 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Both, the N-terminal and the C-terminal part of MLL have been implicated in transcriptional and/or epigenetic regulation. Located 3', the Su(var)3-9, enhancer-of-zeste, trithorax (SET) domain confers histone H3K4 methyltransferase activity to the protein [22]. However, histone H3K4 methylation is a marker for epigenetic activation and it appears unlikely that the loss of an activating function should lead to expression of TSG. Located upstream of the MLL breakpoint cluster region and retained in MLL fusion genes is the CXXC DNA methyltransferase homology domain, which binds CpG rich regions particularly when these are unmethylated [23]. This domain is essential for target gene recognition and is required for transformation by MLL fusion proteins [24]. Therefore, the CXXC domain might direct MLL to transcribed genes or possibly protect CpG islands against methylation. The N-terminal part of MLL has also been reported to bind menin [25]. MLL and menin are required for cellular transformation and both proteins cooperatively regulate expression of the genes p27Kip1 and p18Ink4c [25,26].
###end p 46
###begin p 47
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 186 189 186 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 402 405 402 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 483 486 483 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 626 632 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 655 658 655 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Thus, regulation of TSG expression and alterations of epigenetic functions of MLL fusion proteins are feasible consequences of MLL translocations, but whether the TSG hypomethylation in MLLmu cell lines described by us is the direct effect of MLL fusion proteins or whether the hypomethylation is rather an indirect consequence, remains to be resolved. For two reasons we favor the latter explanation: MLLmu ALL cell lines do not show the TSG methylation profile that is typical for MLLmu AML suggesting that additional, tissue-specific factors play a role in this context. Furthermore, ChIP-DNA mircroarrays did not identify TIMP3 as target of wild-type MLL, the other two genes not being tested [27]. Future studies will have to provide evidence whether the MLL fusion proteins show altered DNA binding specificities than the wild-type protein allowing access to the promoters of the named TSG.
###end p 47
###begin title 48
Conclusion
###end title 48
###begin p 49
###xml 46 58 46 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLLmu </italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLLwt </italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLLmu </italic>
###xml 305 317 305 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4 </italic>
###xml 321 327 321 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 394 402 394 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL </italic>
###xml 424 429 424 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 632 635 632 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 674 678 674 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL </italic>
###xml 454 459 <span type="species:ncbi:10090">mouse</span>
We describe the conspicuous expression of TSG BEX2, IGSF4 and TIMP3 in MLLmu AML cells. In MLLwt cell lines these genes are silenced by promoter methylation. Transcription could be reactivated by treatment with demethylating agents and HDAC inhibitors. In MLLmu AML cell lines, constitutive expression of BEX2, IGSF4 and TIMP3 was accompanied by promoter hypomethylation. Ectopic expression of MLL-ENL drove upregulation of Bex2 in a tamoxifen-inducible mouse model indicating that the MLL fusion genes were responsible for upregulation of TSG mRNA. Taken together, our results suggest that hypomethylation of TSG characteristic of MLLmu AML cells may be the consequence of MLL gene alterations, including elements responsible for epigenetic regulation.
###end p 49
###begin title 50
Methods
###end title 50
###begin title 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cell lines
###end title 51
###begin p 52
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 403 406 403 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 666 669 666 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 796 799 796 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 873 876 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
The continuous cell lines were either taken from the stock of the cell bank (DSMZ - German Collection of Microorganisms and Cell Cultures) or were generously provided by the original investigators. Detailed references and cultivation protocols have been described previously [28,29]. The following cell lines were tested for TSG methylation: (i) B-cell precursor (BCP) ALL-derived cell lines expressing MLLwt: 380, 697, MHH-CALL-2, MHH-CALL-3, MHH-CALL-4, NALM-6, SUP-B15; (ii) BCP ALL-derived cell lines with MLLmu: KOCL-33 t(11;19), KOCL-45 t(4;11), KOCL-58 t(4;11), KOPB-26 t(9;11), KOPN-8 t(11;19), RS4;11 t(4;11), SEM t(4;11); (iii) AML-derived cell lines with MLLwt: AML-193 (M5), MML-1 (M1), MUTZ-3 (M4), OCI-AML5 (M4), SKM-1 (M5), U-937 (M5), YNH-1 (M1); (iv) AML-derived cell lines with MLLmu: IMS-M1 (M5, t(9;11)), ML-2 (M4, t(6;11)), MOLM-13 (M5, t(9;11)), MONO-MAC-6 (M5, t(9;11)), MV4;11 (M5, t(4;11)), NOMO-1 (M5, t(9;11)), THP-1 (M5, t(9;11)).
###end p 52
###begin title 53
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tissue samples
###end title 53
###begin p 54
###xml 348 351 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 163 170 <span type="species:ncbi:9606">patient</span>
After informed consent was given, bone marrow or peripheral blood specimens were obtained during routine clinical assessment of 40 AML patients. The collection of patient samples for analysis of genetic changes was approved by the local ethics committee. DNA extraction was performed from unselected cells from bone marrow or peripheral blood. The MLLwt/mu status of primary samples was assessed with long-distance PCR analysis, as described previously [30].
###end p 54
###begin title 55
Methylation-specific multiplex ligation-dependent probe amplification assay
###end title 55
###begin p 56
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 609 614 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HhaI </italic>
###xml 1006 1011 1006 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 1033 1036 1033 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
###xml 1300 1303 1300 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
###xml 1398 1401 1398 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hha</italic>
###xml 1554 1559 1546 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 1604 1609 1596 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 1655 1660 1647 1652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 1706 1711 1698 1703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
The MS-MLPA assay (ME001B; MRC-Holland, Amsterdam, Netherlands) simultaneously detects copy number changes and CpG methylation of the promoter regions of 24 different TSG. This semi-quantitative technique is based on digestion of DNA with the methylation-sensitive restriction enzyme HhaI (Fermentas, St. Leon-Rot, Germany) and a subsequent multiplex PCR followed by fragment analysis via capillary electrophoresis [31]. MS-MLPA data were analysed using a Microsoft Excel spreadsheet designed specifically for the ME001B assay. Levels of methylation were calculated by comparing the relative peak area of the HhaI digested ligation product with the corresponding ligation product from the undigested sample. Peak areas were normalised relative to neighbouring control ligation products prior to comparison as recommended by MRC-Holland. The spreadsheet for the analysis of the ME001B kit is freely available for download and use on the National Genetics Reference Laboratory website at . For assessment of BEX2 promoter methylation, HhaI-digested and undigested DNA was used as template for subsequent quantitative real-time PCR using SYBR GREEN PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in a 7500 Applied Biosystems real-time PCR system. The sequence flanked by primer pair A lacked HhaI sites, and was used as endogenous control. Sequence amplified by primer pair B contained two HhaI sites. The percentage of non-cleaved and thus methylated template in comparison to the undigested sample was calculated using the DeltaDeltaCt-method. BEX2 A forward: 5'-GGT TGG TGA GAA GGA GGG TG-3'; BEX2 A reverse: 5'-GAG ACA CGA GTG ACG ACT GCA-3'; BEX2 B forward: 5'-TGG AGA GGA CGG AGA TGA GTG-3'; BEX2 B reverse: 5'-CAC CCT CCT TCT CAC CAA CC-3'. Methylation was scored positive when the calculated methylation percentage was >/= 10%.
###end p 56
###begin title 57
Methylation-specific polymerase chain reaction (MSP)
###end title 57
###begin p 58
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
Bisulfite conversion of DNA was performed as described by the supplier (Active Motif, Rixensart, Belgium). For detecting TSG promoter methylation, we performed nested PCR with first round primers amplifying converted DNA independently of the methylation status (bisulfite-specific PCR), while second round primers for M- and U-PCR specifically recognized the methylated or unmethylated versions of the promoter. PCR products of the initial bisulfite-specific PCR were diluted 1:100 for subsequent M- and U-PCR. PCR conditions and primer sequences are listed in Additional file 5. Epitect PCR Control DNA (Qiagen, Hilden, Germany) was used as control for methylated and unmethylated templates.
###end p 58
###begin title 59
Bisulfite sequencing
###end title 59
###begin p 60
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 285 291 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
To confirm methylation status of the IGSF4 promoter, DNA of cell lines and AML patients was bisulfite converted according to the manufacturer's instructions (Active Motif). Subsequently, amplification of the IGSF4 promoter region (559 bp) was performed using primers IGSF4 BSP fwd and IGSF4 BSP rev, specifically binding bisulfite converted DNA (for primer sequence and PCR conditions see Additional file 5). Resulting IGSF4 fragments were purified, cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and sequenced. Sequences were evaluated using BiQ Analyzer  and had to conform to at least 90% bisulfite conversion rate. In addition, identical clones were excluded from the analysis.
###end p 60
###begin title 61
Expression of tumor suppressor genes
###end title 61
###begin p 62
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2 </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RARB </italic>
###xml 472 478 472 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 517 521 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 644 648 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tbp </italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 716 721 716 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bex2 </italic>
###xml 765 769 765 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tbp </italic>
###xml 813 817 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tbp </italic>
###xml 396 401 <span type="species:ncbi:9606">human</span>
###xml 558 563 <span type="species:ncbi:10090">mouse</span>
Quantitative PCR was performed on a 7500 Applied Biosystems (Darmstadt, Germany) real-time PCR system using the manufacturer's protocol. RNA was prepared using the Trizol reagent (Invitrogen, Karlsruhe, Germany). For mRNA quantification, reverse transcription was performed using the SuperScript II reverse transcriptase kit (Invitrogen). TaqMan probes (Applied Biosystems) were used to quantify human BEX2 (Hs 00218464m1), IGSF4 (Hs 00204937m1), RARB (Hs 00233407m1) and TIMP3 (Hs 00927216m1) expression levels with TBP as endogenous control. Expression of mouse Bex2 was assessed using the SYBR GREEN PCR Master Mix (Applied Biosystems) with Tbp as internal control. Bex2 forward: 5'-GCG AGC GGG ACA GAT TGA C-3'; Bex2 reverse: 5'-TCC ATT TCT CCT GGG CCT ATC-3'. Tbp forward: 5'-ACC AGA ACA ACA GCC TTC CAC-3'; Tbp reverse: 5'-TGC CGT AAG GCA TCA TTG GAC-3'. Relative expression levels were calculated using the DeltaDeltaCt-method.
###end p 62
###begin title 63
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL</italic>
Induction of MLL-ENL
###end title 63
###begin p 64
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL-ENL</italic>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 228 234 <span type="species:ncbi:10090">Murine</span>
Mouse bone marrow cell lines MLL-ENL-ERtm 1 and 3 were maintained in RPMI 1640 medium supplemented with 10% FBS (Sigma, Taufkirchen, Germany), IL-3 (5 ng/ml), GM-CSF (5 ng/ml), IL-6 (5 ng/ml), SCF (50 ng/ml) and 4-OHT (100 nM). Murine cytokines were obtained from Richter-Helm (BioLogics, Hamburg, Germany) and 4-OHT was purchased from Sigma. 4-OHT releases MLL-ENL from a heat-shock protein complex thereby activating the fusion protein [21]. Note that MLL-ENL is essentially required for the continuous proliferation of this cell line.
###end p 64
###begin title 65
Treatment with demethylating agents and inhibitors of histone deacetylases
###end title 65
###begin p 66
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
Aza (Sigma) was used to verify the effect of methylation on expression of TSG. The HDAC inhibitor TSA (Sigma) was applied for testing the role of histone acetylation for TSG expression. Cells were seeded at a cell density of 5 x 105 cells/ml, Aza was added at a final concentration of 5 muM. Control cells were treated with 0.05% DMSO. After 2 d, half of the medium was replenished with medium with/without Aza (5 muM). TSA (2 muM final concentration) was added for the last 24 h of cultivation. After 4 d, cells were harvested to prepare RNA and protein.
###end p 66
###begin title 67
Histone purification and Western blot analysis
###end title 67
###begin p 68
###xml 481 492 <span type="species:ncbi:3704">horseradish</span>
Histones were purified according to the protocol of the supplier (Active Motif). Then, 3.3 mug or 10 mug protein were separated by electrophoresis (15% SDS gels) to detect histones and acetylated histones, respectively. Anti acetyl histone H4K12 antiserum was obtained from Biomol/Upstate (Hamburg, Germany), anti histone H4 monoclonal Ab was purchased from Abcam (Cambridge, United Kingdom). Specific bands on nitrocellulose membranes were visualized with the biotin/streptavidin-horseradish peroxidase system (Amersham, Freiburg, Germany) in combination with the "Renaissance Western Blot Chemoluminescence Reagent" protocol (DuPont, Bad Homburg, Germany).
###end p 68
###begin title 69
Competing interests
###end title 69
###begin p 70
The authors declare that they have no competing interests.
###end p 70
###begin title 71
Authors' contributions
###end title 71
###begin p 72
###xml 170 173 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 180 183 180 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
SR designed parts of the study and performed MS-MLPA, MSP analysis, sequencing of bisulfite-converted DNA and co-wrote the manuscript, WGD established MLPA, CM performed MLLwt and MLLmu analysis for primary AML samples, RM provided patient samples and gave good advice, MS performed knock-down experiments, RS provided MLL-ENL-ERtm mouse cell lines and gave good advice, AW established the spreadsheets for the evaluation of MS-MLPA experiments, HGD provided cell lines and critically read the manuscript, HQ designed the study and wrote the manuscript.
###end p 72
###begin title 73
Supplementary Material
###end title 73
###begin title 74
Additional file 1
###end title 74
###begin p 75
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Methylation status of 24 TSG in 28 acute leukemia cell lines according to MS-MLPA</bold>
###xml 256 263 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2A </italic>
###xml 267 273 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN2B</italic>
Methylation status of 24 TSG in 28 acute leukemia cell lines according to MS-MLPA. Shown is the promoter methylation status of TSG. Green: methylation >/= 10%; yellow: methylation < 10%. TSG are arranged from left to right according to gene locus. For TSG CDKN2A and CDKN2B, ploidy status is indicated by numbers. Data shown are from one experiment per cell line. Reproducibility of MS-MLPA results was confirmed by up to four repetitions of analyses with selected cell lines.
###end p 75
###begin p 76
Click here for file
###end p 76
###begin title 77
Additional file 2
###end title 77
###begin p 78
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MSP analyses of <italic>BEX2</italic>, <italic>IGSF4 </italic>and <italic>TIMP3 </italic>in AML cell lines</bold>
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 130 133 130 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2</italic>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGSF4 </italic>
###xml 587 592 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3</italic>
MSP analyses of BEX2, IGSF4 and TIMP3 in AML cell lines. Methylation status of BEX2, IGSF4 and TIMP3 were determined in MLLwt and MLLmu AML cell lines by MSP to control methylation status as determined by MS-MLPA. Results for M- and U-PCR are shown as well as the methylation status according to MS-MLPA. Performance of MS-MLPA as a classification system for methylated or unmethylated TSG was evaluated using a confusion matrix. Overall, the results of the techniques were in good concordance with an accuracy of 0.83. In detail, accuracy was 0.86 for BEX2, 0.93 for IGSF4 and 0.71 for TIMP3.
###end p 78
###begin p 79
Click here for file
###end p 79
###begin title 80
Additional file 3
###end title 80
###begin p 81
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Methylation analyses in primary AML samples</bold>
###xml 106 124 106 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BEX2, IGSF4, RARB </italic>
###xml 128 134 128 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP3 </italic>
###xml 148 151 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
Methylation analyses in primary AML samples. Results of promoter methylation analysis according to MSP of BEX2, IGSF4, RARB and TIMP3 are shown for MLLmu and MLLwt AML patients
###end p 81
###begin p 82
Click here for file
###end p 82
###begin title 83
Additional file 4
###end title 83
###begin p 84
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activating histone modifications induced by TSA</bold>
###xml 206 209 206 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLL</italic>
Activating histone modifications induced by TSA. TSA effected acetylation of histone H4K12, as assessed by Western blot analysis. Aza treatment was not alone sufficient to induce histone H4K12 acetylation. MLLwt cell lines AML-193, SKM-1 and U-937 were treated with TSA (2 muM, 1 d), Aza (5 muM, 4 d) or a combination of both reagents.
###end p 84
###begin p 85
Click here for file
###end p 85
###begin title 86
Additional file 5
###end title 86
###begin p 87
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primers for methylation-specific PCR</bold>
Primers for methylation-specific PCR. Primers and reaction conditions for BSP and MSP are listed.
###end p 87
###begin p 88
Click here for file
###end p 88
###begin title 89
Acknowledgements
###end title 89
###begin p 90
Acknowledgements: We thank Rod AF MacLeod for critically reading the manuscript. This study was in part supported by a grant from the Deutsche Krebshilfe (107819) to RM.
###end p 90
###begin article-title 91
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
###end article-title 91
###begin article-title 92
Expression of HOX genes in acute leukemia cell lines with and without MLL translocations
###end article-title 92
###begin article-title 93
Expression of BEX1 in acute myeloid leukemia with MLL rearrangements
###end article-title 93
###begin article-title 94
Cloning and expression pattern of a spermatogenesis-related gene, BEX1, mapped to chromosome Xq22
###end article-title 94
###begin article-title 95
Epigenetic regulation of brain expressed X-linked-2, a marker for acute myeloid leukemia with mixed lineage leukemia rearrangements
###end article-title 95
###begin article-title 96
Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma
###end article-title 96
###begin article-title 97
Epigenetics in cancer
###end article-title 97
###begin article-title 98
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
###end article-title 98
###begin article-title 99
###xml 35 40 <span type="species:ncbi:9606">human</span>
A gene hypermethylation profile of human cancer
###end article-title 99
###begin article-title 100
Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg
###end article-title 100
###begin article-title 101
Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior
###end article-title 101
###begin article-title 102
Discovery of novel epigenetic markers in non-Hodgkin's lymphoma
###end article-title 102
###begin article-title 103
###xml 74 79 <span type="species:ncbi:9606">human</span>
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies
###end article-title 103
###begin article-title 104
Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived
###end article-title 104
###begin article-title 105
###xml 43 48 <span type="species:ncbi:9606">human</span>
A systematic profile of DNA methylation in human cancer cell lines
###end article-title 105
###begin article-title 106
Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia
###end article-title 106
###begin article-title 107
Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia
###end article-title 107
###begin article-title 108
CpG islands and genes
###end article-title 108
###begin article-title 109
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
###end article-title 109
###begin article-title 110
DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia
###end article-title 110
###begin article-title 111
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization
###end article-title 111
###begin article-title 112
MLL targets SET domain methyltransferase activity to Hox gene promoters
###end article-title 112
###begin article-title 113
The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation
###end article-title 113
###begin article-title 114
Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein
###end article-title 114
###begin article-title 115
Interaction of MLL amino terminal sequences with menin is required for transformation
###end article-title 115
###begin article-title 116
Menin and MLL cooperatively regulated expression of cyclin-dependent kinase inhibitors
###end article-title 116
###begin article-title 117
Global and Hox-specific roles for the MLL1 methyltransferase
###end article-title 117
###begin article-title 118
Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations
###end article-title 118
###begin article-title 119
Diagnostic tool for the identification of MLL rearrangements including unknown partner genes
###end article-title 119
###begin article-title 120
Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences
###end article-title 120

